DK1128826T3 - Chromonformulering til enteral frigørelse af aktivt stof - Google Patents

Chromonformulering til enteral frigørelse af aktivt stof

Info

Publication number
DK1128826T3
DK1128826T3 DK99954194T DK99954194T DK1128826T3 DK 1128826 T3 DK1128826 T3 DK 1128826T3 DK 99954194 T DK99954194 T DK 99954194T DK 99954194 T DK99954194 T DK 99954194T DK 1128826 T3 DK1128826 T3 DK 1128826T3
Authority
DK
Denmark
Prior art keywords
chromone
formulation
active substance
enteral release
enteral
Prior art date
Application number
DK99954194T
Other languages
English (en)
Inventor
Alexander James Wigmore
Original Assignee
Hewlett Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hewlett Healthcare Ltd filed Critical Hewlett Healthcare Ltd
Application granted granted Critical
Publication of DK1128826T3 publication Critical patent/DK1128826T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Medicines Containing Plant Substances (AREA)
DK99954194T 1998-11-11 1999-11-09 Chromonformulering til enteral frigørelse af aktivt stof DK1128826T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824604.4A GB9824604D0 (en) 1998-11-11 1998-11-11 Treatment of allergic conditions
PCT/GB1999/003731 WO2000027392A1 (en) 1998-11-11 1999-11-09 Chromone enteric release formulation

Publications (1)

Publication Number Publication Date
DK1128826T3 true DK1128826T3 (da) 2004-04-05

Family

ID=10842171

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99954194T DK1128826T3 (da) 1998-11-11 1999-11-09 Chromonformulering til enteral frigørelse af aktivt stof

Country Status (12)

Country Link
US (2) US7258872B1 (da)
EP (1) EP1128826B1 (da)
JP (1) JP4558207B2 (da)
AT (1) ATE258049T1 (da)
AU (1) AU1061400A (da)
CA (1) CA2350519C (da)
DE (1) DE69914360T2 (da)
DK (1) DK1128826T3 (da)
ES (1) ES2219075T3 (da)
GB (1) GB9824604D0 (da)
PT (1) PT1128826E (da)
WO (1) WO2000027392A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
AU2001296770A1 (en) * 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
US8817116B2 (en) 2011-10-28 2014-08-26 Lg Innotek Co., Ltd. Camera module
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
IT201700030541A1 (it) 2017-03-20 2018-09-20 Federica Livieri Composizione e kit per uso nella prevenzione dell’onicomicosi recidivante

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1423985A (en) 1972-02-15 1976-02-04 Fisons Ltd Pharmaceutical compositions containing bischromonyloxy compounds
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
GB1525294A (en) 1976-06-22 1978-09-20 Fisons Ltd Compositions containing substituted bis-chromonyl compounds
GB1549229A (en) 1976-09-23 1979-08-01 Fisons Ltd High density sodium cromoglycate
GB1569612A (en) 1977-01-13 1980-06-18 Fisons Ltd Disodium cromoglycate pellets or granules
GB1557082A (en) * 1977-01-25 1979-12-05 Fisons Ltd Pharmaceutical mixture containing an antiinflammatory
GB1595220A (en) 1977-12-23 1981-08-12 Fisons Ltd Tablets containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane
GB2086227B (en) 1980-11-05 1984-10-10 Fisons Ltd Sodium cromoglycate reconstitutable powders
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB2324962B (en) * 1997-05-10 2001-10-03 Hewlett Healthcare Ltd Treatment of allergic conditions
GB9709451D0 (en) 1997-05-10 1997-07-02 Hewlett Healthcare Limited Treatment of allergic conditions
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
DE19900116C2 (de) 1999-01-05 2002-02-14 Univ Muenchen Tech Vorrichtung zum Erzeugen von Brenngas durch allotherme Vergasung von Biomasse

Also Published As

Publication number Publication date
JP2002529413A (ja) 2002-09-10
DE69914360D1 (de) 2004-02-26
JP4558207B2 (ja) 2010-10-06
ATE258049T1 (de) 2004-02-15
CA2350519C (en) 2011-09-13
US7258872B1 (en) 2007-08-21
EP1128826A1 (en) 2001-09-05
DE69914360T2 (de) 2004-11-11
AU1061400A (en) 2000-05-29
US20070036860A1 (en) 2007-02-15
PT1128826E (pt) 2004-06-30
ES2219075T3 (es) 2004-11-16
CA2350519A1 (en) 2000-05-18
GB9824604D0 (en) 1999-01-06
WO2000027392A1 (en) 2000-05-18
EP1128826B1 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
DK1128826T3 (da) Chromonformulering til enteral frigørelse af aktivt stof
Li et al. Cytoprotective effects of dietary flavonoids against cadmium‐induced toxicity
Torres-Carro et al. Inhibition of pro-inflammatory enzymes by medicinal plants from the Argentinean highlands (Puna)
Witaicenis et al. Intestinal anti-inflammatory activity of esculetin and 4-methylesculetin in the trinitrobenzenesulphonic acid model of rat colitis
Fusi et al. An in vitro comparative study of the antioxidant activity and SIRT1 modulation of natural compounds
Kong et al. Gut microbiota modulation by polyphenols from Aronia melanocarpa of LPS-induced liver diseases in rats
Huang et al. Incremental extraction of flavonoids from Penthorum chinense Pursh for alleviating dextran sulfate sodium-induced mouse colitis by regulating gut microbiota
NO20021830D0 (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
Zha et al. Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression
Dubey et al. Rutin exerts antiulcer effect by inhibiting the gastric proton pump
Ganapaty et al. Free radical scavenging activity of gossypin and nevadensin: An: In-vitro: Evaluation
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
DE60327438D1 (de) Amino-substituierte cyclohexan derivate zur behandlung bakterieller infektionen
NO20061911L (no) Immunogene sammensetninger
ATE485046T1 (de) Pharmazeutische zusammensetzung enthaltend cordycepin zur behandlung und prävention von fettleibigkeit
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
Wu et al. Preventive effect of flavonoid extract from the peel of Gonggan (Citrus reticulata Blanco Var. Gonggan) on CCl4-induced acute liver injury in mice
Lv et al. Protective effects and potential underlying mechanisms of sodium copper chlorophyllin against ethanol-induced gastric ulcer in mice
Lv et al. Phytochemical compositions and antioxidant and anti‐inflammatory activities of crude extracts from Ficus pandurata H.(Moraceae)
NO20021640D0 (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Ginko Biloba
WO2005096704A3 (en) Cholesterol lowering composition
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
Yang et al. The protective effect of nostoc commune Vauch. polysaccharide on alcohol‐induced acute alcoholic liver disease and gut microbiota disturbance in mice